Have a prior history of primary endometrial cancer, except: Stage IA cancer; superficial myometrial invasion, without lymphovascular invasion; grade less than (<)  or poorly differentiated subtypes, and this includes papillary serous, clear cell or other International Federation of Gynecological Oncologists (FIGO) Grade  lesions
Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, unless all of the following conditions are met: stage not greater than I-A, grade  or , no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including serous, clear cell or other FIGO grade  lesions
Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other Federation of Gynecology and Obstetrics (FIGO) grade  lesions
Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, unless all of the following conditions are met: stage not greater than I-A, grade  or , no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including serous, clear cell or other FIGO grade  lesions
Diagnosis of International Federation of Gynecology and Obstetrics (FIGO) grade  endometrioid cancer, serous, clear cell, or mixed high grade endometrial cancer with confirmation on research-related endometrial biopsy
Patients with a history of primary endometrial cancer are excluded unless the following conditions are met:\r\n* Stage not greater than IA\r\n* Not a poorly differentiated subtype (including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics [FIGO] grade  lesions)
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:\r\n* Treated limited stage basal cell or squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the breast or cervix\r\n* Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade  or , no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade  lesions\r\n* Prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence
Uterine cancer participants will be International Federation of Gynecology and Obstetrics (FIGO) stage IIIC and may have endometrioid cancer, clear cell cancer, uterine papillary serous cancer, carcinosarcoma, or endometrial stromal sarcoma
Patients with a history of other invasive malignancies, with the exception of nonmelanoma skin cancer and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy\r\n* Carcinoma in situ of the breast or cervix\r\n* Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade  or , no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell, or other federation of gynecology and obstetrics (FIGO) grade  lesions
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:\r\n* Treated limited stage basal cell or squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the breast or cervix\r\n* Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade  or , no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) grade  lesions\r\n* Prior cancer treated with a curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence
Patients with synchronous primary endometrial cancer or a past history of endometrial cancer, unless all of the following conditions are met:\r\n* Stage not greater than IB\r\n* No more than superficial myometrial invasion\r\n* No vascular or lymphatic invasion\r\n* No poorly differentiated subtypes, including papillary serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade  lesions
Participants with synchronous primary endometrial cancer, or a past history of endometrial cancer unless all of the following conditions are met: endometrial cancer stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated subtypes including serous, clear cell, or other FIGO grade  lesions.
Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics (FIGO) grade  lesions
Patients with a past history of synchronous endometrial cancer are excluded unless all of the following conditions are met: stage not greater than I-A (International Federation of Gynecology and Obstetrics [FIGO]  staging criteria); no more than superficial myometrial invasion (< %), without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO grade  lesions, and it has been greater than  years since diagnosis and there have been no recurrences
Participants with any concomitant or prior invasive malignancies are ineligible with the following exceptions:\r\n* Treated limited-stage basal cell or squamous cell carcinoma of the skin\r\n* Carcinoma in situ of the breast or cervix\r\n* Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade  or , no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade  lesions\r\n* Prior cancer treated with curative intent with no evidence of recurrent disease  years following diagnosis and judged by the investigator to be at low risk of recurrence
Patients with synchronous primary endometrial cancer or a past history of endometrial cancer, unless all of the following conditions are met: \r\n* Stage not greater than IB \r\n* No more than superficial myometrial invasion \r\n* No vascular or lymphatic invasion \r\n* No poorly differentiated subtypes, including serous, clear cell or other International Federation of Gynecologists and Obstetricians (FIGO) grade  lesions
Patients with a known synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than IA, no more than superficial myometrial invasion, without vascular or lymphatic invasion, no poorly differentiated subtypes (including papillary serous, clear cell or other FIGO grade  lesions)
Patients with a synchronous primary endometrial cancer, or a past history of primary endometrial cancer are excluded unless all of the following conditions are met: stage not greater than stage IA; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade  lesions
Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: Stage not greater than IB; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other FIGO Grade  lesions.
Patients with synchronous primary endometrial cancer or a past history of endometrial cancer, unless all of the following conditions are met:\r\n* Stage not greater than IB\r\n* No more than superficial myometrial invasion\r\n* No vascular or lymphatic invasion\r\n* No poorly differentiated subtypes, including serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade  lesions
